OTC: BXPHF - Botanix Pharmaceuticals Limited

Lønnsomhet i seks måneder: +60%
Sektor: Healthcare

Kampanjeplan Botanix Pharmaceuticals Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections.

flere detaljer
Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.botanixpharma.com
Цена ао 0.289
Prisendring per dag: 0% (0.32)
Prisendring per uke: +24.03% (0.258)
Prisendring per måned: +33.33% (0.24)
Prisendring over 3 måneder: +10.73% (0.289)
Prisendring over seks måneder: +60% (0.2)
Prisendring per år: +166.67% (0.12)
Prisendring over 3 år: +611.11% (0.045)
Prisendring over 5 år: +45.45% (0.22)
Prisendring over 10 år: 0% (0.32)
Prisendring siden begynnelsen av året: +33.33% (0.24)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 108.99 1
P/BV 2.07 7
P/E 0 0
EV/EBITDA -10.61 0
Total: 3.38

Effektivitet

Navn Betydning Karakter
ROA, % -18.53 0
ROE, % -19.38 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0.1372

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0088 10
Total: 7.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -72.68 0
Lønnsomhet Ebitda, % -16.84 0
Lønnsomhet EPS, % 4.96 1
Total: 1.4
Flere detaljer



Veileder Stillingstittel Betaling Fødselsår
Mr. Vincent P. Ippolito MD & Executive Chairman 244.45k 1959 (66 år)
Dr. Howie McKibbon Chief Executive Officer 393.72k
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Executive Director 258.29k 1973 (52 år)
Dr. Jack Hoblitzell Ph.D. Senior Vice President of Pharmaceutical Development N/A
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser N/A 1959 (66 år)
Dr. Boris Meyerson Ph.D. Chief Business Officer
Mr. David Morgan Head of Corporate Affairs
Mr. Graeme Morissey Chief Financial Officer

Adresse: Australia, West Perth, 41 – 47 Colin Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.botanixpharma.com